BeOne Medicines Stock Forecast
NASDAQ: ONCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 1:48 PM ET
ONC analyst consensus
Consensus (28 analysts)
strong_buy
Avg. price target
$435.20+25.26%
- Strong buy 7
- Buy 20
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 28 Wall Street analysts covering BeOne Medicines (2026-10-07), 27 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $435.20, with a high estimate of $528.00 and a low estimate of $370.00. The average target implies upside of 25.3% from the current price of $347.45.
The spread between the highest and lowest targets is 42.7%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ONC.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 7 | 25% |
| Buy | 20 | 71% |
| Hold | 1 | 4% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $370.00 | +6.49% |
| Average target | $435.20 | +25.26% |
| High target | $528.00 | +51.97% |